Hospital Universitario De La Plana

Villarreal 10 trials 6 recruiting

10 Registered trials

6 Currently recruiting

Organisation

Hospital Universitario De La Plana

Location

Villarreal, Spain

Identifier

ORG-100042340

Address

Carretera De Vila-Real A Burriana Km 0.5, 12540, Spain

Departments

Alergología
Alergology
Allergiology
Allergology
Allergy
Anesthesia
Neumology
Paritorio

Clinical trials at this site (10)

Search interface

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of… Recruiting

2023-508547-51-00 Aetiological treatment of moderate-to-severe allergic r 5 2025-11-18
Is magnesium sulfate an alternative with an analgesic and safety profile equivalent to dexmedetomidine as an adjuvant to ropivacaine in erec… Recruiting

2025-523152-31-00 Breast cancer 6 2026-01-26
A randomized clinical trial to compare topical lidocaine-prilocaine cream (Emla) versus 2% lidocaine infiltration to first-degree perineal t… Recruiting

2024-512728-12-00 First-dregree perineal laceration 6 2024-08-12
A study to investigate the efficacy and safety of tezepelumab compared with placebo in children 5 to < 12 years old with severe asthma Recruiting

2022-502984-39-00 Severe Uncontrolled Asthma Asthma (an illness that caus 5 2023-12-13
EVALUATION OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS IMMUNOTHERAPY (BELTAVAC®) WITH POLYMERIZED ALLERGENIC EXTRACT OF HOUSE DUST MITE MIXTU… Recruiting

2024-516893-31-01 Allergic rhinoconjunctivitis due to exposure of house d 5 2022-01-31
Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/D… Ended

2024-518519-20-01 moderate/severe allergic rhinitis/rhinoconjunctivitis w 4 2025-04-10
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Chronic Spontaneous Urticaria 5 2024-12-16
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28